José Ponce

6PUBLICATIONS
92CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 05, 2026
A systemic immune signature stratifies early-stage breast cancer patients and reveals soluble IL-2RA and PD-1 as potential independent prognostic biomarkers.

|May 26, 2026
Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

|Dec 12, 2025
Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.

Miguel Martín, Ángel L Guerrero-Zotano, María E Pérez-López

|Dec 03, 2025
Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial.

Eva Ciruelos, Tomás Pascual, Guillermo Villacampa

|Feb 08, 2025
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study.

Regina Peña-Enríquez, Begoña Bermejo, Marina Pollán

|Jan 07, 2022
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).

Erica L Mayer, Christian Fesl, Dominik Hlauschek

Pageof 1

Frequent Collaborators

3 joint publications

Rosalía Caballero

2 joint publications

Miguel Martín

2 joint publications

Angel L Guerrero-Zotano

2 joint publications

Manuel Ruiz-Borrego